98%
921
2 minutes
20
Chandipura virus (CHPV), a member of the family Rhabdoviridae, has garnered attention due to its significant implications on human health, particularly in India, where it has contributed to encephalitis outbreaks. This review provides a full-spectrum analysis of CHPV, detailing its origin, historical context, and geographical distribution, which primarily spans India and parts of Africa. CHPV is predominantly transmitted through infected sandflies, although alternative transmission routes cannot be overruled. Neurotropism plays a vital role in CHPV-associated pathogenesis, leading to severe neurological ailments, including encephalitis and fatalities among children at a significantly high rate. Current diagnostic approaches for CHPV infection harness molecular biology tools like PCR for viral RNA detection and serological methods to identify antibodies. Effective therapeutic strategies remain limited, with antivirals such as Favipiravir indicating strong prospects in preclinical studies. We also discuss various animal models used in CHPV research, including murine models, offering critical insights into the CHPV pathogenesis and evaluating the efficacy of potential therapeutic interventions. Concisely, this review underscores the significance of robust monitoring and further research to enhance our understanding of CHPV and develop effective strategies for its control and prevention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.virol.2025.110541 | DOI Listing |
J Infect Dis
September 2025
Indian Institute of Science Education and Research (IISER) Bhopal, Bhopal, MP, India.
Chandipura virus (CHPV), a Rhabdoviridae family member, is an emerging neurotropic pathogen responsible for acute encephalitis outbreaks in children, mainly in India. Despite its public health relevance, the mechanisms underlying CHPV entry into host cells remain poorly understood. In this study, we used pharmacological inhibitors in Vero cells to dissect the virus's entry pathways.
View Article and Find Full Text PDFViruses
July 2025
Arboviral Diseases Branch, Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention, Fort Collins, CO 80521, USA.
In December 2023, infections of western equine encephalitis virus (WEEV) within Argentina were reported to the World Health Organization (WHO). By April 2024, more than 250 human infections, 12 of which were fatal, and 2500 equine infections were identified in South America. Laboratory diagnosis and surveillance in affected countries were hindered by a lack of facilities equipped with BSL-3 laboratories, as confirmatory serodiagnosis for WEEV requires live virus in the plaque reduction neutralization test (PRNT).
View Article and Find Full Text PDFViruses
July 2025
State Key Laboratory of Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin 150069, China.
Nipah virus (NiV) is a highly pathogenic bat-borne zoonotic pathogen that poses a significant threat to human and animal health, with fatality rates exceeding 70% in some outbreaks. Despite its significant public health impact, there are currently no licensed vaccines or specific therapeutics available. Various virological tools-such as reverse genetics systems, replicon particles, VSV-based pseudoviruses, and recombinant Cedar virus chimeras-have been widely used to study the molecular mechanisms of NiV and to support vaccine development.
View Article and Find Full Text PDFViruses
July 2025
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China.
Recombinant vesicular stomatitis virus (rVSV) is a promising viral vaccine vector for addressing the COVID-19 pandemic. Inducing mucosal immunity via the intranasal route is an ideal strategy for rVSV-based vaccines, but it requires extremely stringent safety standards. In this study, we constructed two rVSV variants with amino acid mutations in their M protein: rVSV-M2 with M33A/M51R mutations and rVSV-M4 with M33A/M51R/V221F/S226R mutations, and developed COVID-19 vaccines based on these attenuated vectors.
View Article and Find Full Text PDFFront Immunol
August 2025
Research and Development Department, Joint Biosciences (SH) Ltd, Shanghai, China.
Introduction: Vesicular stomatitis virus (VSV) is a promising oncolytic viral platform due to its short replication cycle, broad tissue tropism, low natural infection rate in humans, and a small genome that is easy to genetically manipulate. Leveraging these advantages, we developed an attenuated oncolytic VSV-based virus, OVV-01, encoding the tumor-associated antigen (TAA) NY-ESO-1.
Methods: OVV-01 was constructed by inserting the NY-ESO-1 gene into a VSV backbone.